

Arnaud Scherpereel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6035812/publications.pdf>

Version: 2024-02-01

66
papers

6,025
citations

159585

30
h-index

123424

61
g-index

70
all docs

70
docs citations

70
times ranked

5185
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	10.7	773
2	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1405-1414.	13.7	753
3	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386.	13.7	638
4	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	10.7	356
5	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 239-253.	10.7	342
6	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	1.6	317
7	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	30.7	225
8	Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1155-1160.	5.6	218
9	Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. <i>Clinical Cancer Research</i> , 2007, 13, 2928-2935.	7.0	211
10	Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1541-1549.	1.6	199
11	ERS/EACTS statement on the management of malignant pleural effusions. <i>European Respiratory Journal</i> , 2018, 52, 1800349.	6.7	179
12	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	6.7	151
13	Deep Learning on Chest X-ray Images to Detect and Evaluate Pneumonia Cases at the Era of COVID-19. <i>Journal of Medical Systems</i> , 2021, 45, 75.	3.6	132
14	Novel therapies for malignant pleural mesothelioma. <i>Lancet Oncology</i> , The, 2018, 19, e161-e172.	10.7	121
15	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 569-580.	10.7	117
16	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	1.1	106
17	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018, 116, 62-66.	2.0	94
18	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1269-1283.	1.1	87

#	ARTICLE	IF	CITATIONS
19	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMANDER A Double-Blind, Randomized, Phase II Study. Journal of Clinical Oncology, 2019, 37, 790-798.	1.6	79
20	Immunotherapy in Malignant Pleural Mesothelioma. Frontiers in Oncology, 2020, 10, 187.	2.8	66
21	Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer, 2007, 110, 2248-2252.	4.1	65
22	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine, 2019, 48, 191-202.	6.1	55
23	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2020, 58, 1-24.	1.4	50
24	Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis. Drugs, 2019, 79, 1567-1582.	10.9	49
25	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clinical Lung Cancer, 2019, 20, e564-e575.	2.6	49
26	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2022, 23, 758-767.	10.7	49
27	Use of Immune Checkpoint Inhibitors in Mesothelioma. Current Treatment Options in Oncology, 2019, 20, 18.	3.0	46
28	Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer, 2013, 13, 324.	2.6	37
29	Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.. Journal of Clinical Oncology, 2017, 35, LBA8507-LBA8507.	1.6	36
30	Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 To	2.5	36
31	Epidemiological Observations on the Association Between Anosmia and COVID-19 Infection: Analysis of Data From a Self-Assessment Web Application. Journal of Medical Internet Research, 2020, 22, e19855.	4.3	33
32	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Medicine, 2021, 13, 113.	8.2	31
33	Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.. Journal of Clinical Oncology, 2016, 34, 8502-8502.	1.6	26
34	Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study. BMC Cancer, 2018, 18, 178.	2.6	25
35	Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.. Journal of Clinical Oncology, 2015, 33, 7500-7500.	1.6	22
36	Inequalities in lung cancer: a world of EGFR. European Respiratory Journal, 2016, 47, 1502-1509.	6.7	21

#	ARTICLE	IF	CITATIONS
37	Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 193-197.	1.3	19
38	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 387-397.	6.4	19
39	Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 543-552.	3.8	17
40	Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. <i>Cancer Medicine</i> , 2018, 7, 1102-1109.	2.8	15
41	Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?. <i>Annals of Thoracic Surgery</i> , 2015, 99, 2237-2245.	1.3	14
42	PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 778-781.	1.1	14
43	National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohort. <i>International Journal of Clinical Practice</i> , 2021, 75, e14121.	1.7	14
44	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5759-5765.	7.0	13
45	Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e30-e35.	1.1	12
46	Malignant pleural mesothelioma: new treatments, new hopes?. <i>European Respiratory Journal</i> , 2017, 49, 1700319.	6.7	10
47	Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries. <i>BMC Cancer</i> , 2018, 18, 1144.	2.6	9
48	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	2.0	9
49	ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. <i>European Respiratory Journal</i> , 2018, 52, 1800610.	6.7	8
50	Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. <i>Molecular Cancer</i> , 2018, 17, 148.	19.2	8
51	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. <i>Cancers</i> , 2022, 14, 1498.	3.7	8
52	Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series. <i>Scientific Reports</i> , 2020, 10, 11201.	3.3	7
53	Immunotherapy in relapsed mesothelioma. <i>Immunotherapy</i> , 2018, 10, 77-80.	2.0	5
54	Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 18, 155-161.	2.6	4

#	ARTICLE	IF	CITATIONS
55	VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Research, 2015, 1, 00029-2015.	2.6	2
56	Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply. Lancet, The, 2021, 398, 302.	13.7	2
57	Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.. Journal of Clinical Oncology, 2014, 32, TPS7609-TPS7609.	1.6	2
58	Pleural and chest wall tumours. , 2019, , 506-513.		2
59	Reply to K. Masuda et al. Journal of Clinical Oncology, 2019, 37, 2294-2295.	1.6	1
60	Mesothelioma: is chemotherapy alone a thing of the past?. , 2020, , 232-249.		1
61	A defect of amphiregulin release predicted longer survival independently of <scp>YAP</scp> expression in patients with pleural mesothelioma in the <scp>IFCT</scp> – 0701 <scp>MAPS</scp> phase 3 trial. International Journal of Cancer, 2022, 150, 1889-1904.	5.1	1
62	HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers, 2022, 14, 2164.	3.7	1
63	Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future. Current Pulmonology Reports, 2017, 6, 155-159.	1.3	0
64	Malignant Pleural Mesothelioma. , 2022, , 510-514.		0
65	Phase I dose-escalation study of an oral administration of the pan-histone deacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2575-2575.	1.6	0
66	Targeting Angiogenesis in Malignant Pleural Mesothelioma. , 2019, , 235-242.		0